HealthDay News — Patients receiving immunotherapy with antiprogrammed cell death protein-1 (anti-PD-1) and antiprogrammed cell death ligand-1 (anti-PD-L1) monoclonal antibodies may develop uveal effusion, according to a report published online April 12 in JAMA Ophthalmology.

Merina Thomas, MD, from the University of Michigan in Ann Arbor, and colleagues describe 3 patients who developed uveal effusion after initiation of anti-PD-1 and anti-PD-L1 monoclonal antibody therapy. The patients were 2 white men aged 52 and 85 years with metastatic cutaneous melanoma and a 68-year-old African-American man with metastatic adenocarcinoma of the lung. All 3 patients were receiving anti-PD-1 and anti-PD-L1 monoclonal antibody therapy. 

Related Articles

The researchers found that all 3 patients developed uveal effusion within 1 to 2 months after initiation of anti-PD-1 and anti-PD-L1 monoclonal antibody therapy. In 6 to 12 weeks after discontinuation of systemic therapy, uveal effusion resolved completed in 2 patients; uveal effusion persisted in 1 patient who continued therapy.

“Uveal effusion should be considered in patients taking anti-PD-1 and/or PD-L1 monoclonal antibody therapy,” the authors write. “Because of the role of the PD-1 pathway in the inhibition of self-reactive T cells, PD-1 inhibition might lead to inflammation because of immune-related adverse effects.”

One author disclosed financial ties to Castle Biosciences.

Abstract/Full Text (subscription or payment may be required)